Showing 2711-2720 of 4802 results for "".
Go Big or Go Home? Taking MIPS to The Max
https://practicaldermatology.com/topics/practice-management/go-big-or-go-home-taking-mips-to-the-max/20696/Part three in a three-part series on the MIPS “pick-your-pace” transition.Assessing the Need for Re-Excision in Mild to Moderate Dysplastic Nevi
https://practicaldermatology.com/topics/skin-cancer-photoprotection/assessing-the-need-for-re-excision-in-mild-to-moderate-dysplastic-nevi/21247/Re-excision may not be clinically warranted in a majority of cases.Currents: Eczema
https://practicaldermatology.com/topics/atopic-dermatitis/currents-eczema-1/23743/Guiding Patients to Good Skincare
https://practicaldermatology.com/topics/practice-management/guiding-patients-to-good-skincare/20577/A skincare pyramid offers physicians a tool to engage and educate patients about anti-aging skincare options from prevention to reversal.Easing Further Down The Road: Getting Comfortable with MIPS
https://practicaldermatology.com/topics/practice-management/easing-further-down-the-road-getting-comfortable-with-mips/20715/Part two of a three-part series on the MIPS “pick-your-pace” transition.Invasive Melanoma: Incidence, Mortality Continue to Climb
https://practicaldermatology.com/topics/practice-management/invasive-melanoma-incidence-mortality-continue-to-climb/20780/The burden of disease is growing, despite best efforts to combat melanoma.Facing the Impact of Rosacea
https://practicaldermatology.com/columns/clinical-focus-1/facing-the-impact-of-rosacea/23394/New data shed light on the patient experience.Cures All
https://practicaldermatology.com/topics/practice-management/cures-all/20771/What will the 21st Century Cures Act mean for dermatologists?The Molecular Era in Melanoma Treatment
https://practicaldermatology.com/topics/skin-cancer-photoprotection/the-molecular-era-in-melanoma-treatment/21296/Melanoma Treatment Landscape Evolves
https://practicaldermatology.com/topics/skin-cancer-photoprotection/melanoma-treatment-landscape-evolves/21314/The first agent to target the PD-1 pathway, pembrolizumab may prolong life expectancy in some patients.